Undierentiated nasopharyngeal carcinoma (NPC) is an epithelial malignancy that is consistently associated with Epstein-Barr virus (EBV) but which very rarely has p53 gene mutations in primary tumours. Since the tumour suppressor p53 is mutated in most human cancers or the wild type protein is inactivated in a signi®cant number of the remainder, here we have investigated cellular factors that could compromise p53 function in primary NPC. Twenty-®ve primary tumours were judged to carry only wild type p53 by SSCP analysis of all exons and sequence determination of exons 4 ± 9. Only one tumour was found to express signi®cant levels of hMdm2 and in 24/25 there were no detectable mutations or deletions in exons 1b and 2 of the p14 ARF gene. However, immunohistochemistry consistently revealed that all the tumour cells express substantial amounts of the p53-related protein p63. Semi-quantitative RT ± PCR analysis of mRNA from tumour biopsies showed that the dominant species expressed was invariably the truncated DN-isotype. Since this can block p53-mediated transactivation, it is potentially a dominant-negative isoform. In normal nasopharyngeal epithelium the distribution of p63 was restricted to the proliferating basal and suprabasal layers. We suggest that DN-p63 is a good candidate as a suppressor of wild type p53 function in these tumours and also that it may prove to be a valuable diagnostic marker for undierentiated NPC. Oncogene (2000) 19, 3439 ± 3444.
Keywords: p53; p63; p14 ARF ; undierentiated nasopharyngeal carcinoma; NPC Nasopharyngeal cancers originate from various components of the walls of the nasopharynx. Carcinomas that arise from the surface epithelium are by far the most common and the term nasopharyngeal carcinoma (NPC) is generally reserved for these (Klein, 1979) . Non-keratinizing or undierentiated NPC (WHO categories II and III) are invariably associated with Epstein-Barr virus; that is, primary tumours contain EBV DNA together with RNA and protein products of viral gene expression (reviewed in Rickinson and Kie, 1996) . Characteristically these undierentiated tumours include a signi®cant in®ltration of T lymphocytes (reviewed in Niedobitek et al., 1996) , up to 60% fail to express the tumour suppressor protein p16 INK4A (Lo et al., 1995 (Lo et al., , 1996 Sun et al., 1995; Gulley et al., 1998) and ± unlike most human tumours ± nearly 100% are wild type for the p53 tumour suppressor gene (Eert et al., 1992; Sun et al., 1992; Lo et al., 1992; Spruck et al., 1992) . Paradoxically and in contrast to most normal tissues, although only wild type p53 alleles are present, in most NPC sucient p53 is expressed for it to be detectable by immunohistochemistry (Niedobitek et al., 1993; Sheu et al., 1995; Murono et al., 1999) . Since these cells are rapidly proliferating, the p53 protein is assumed to be inactivated.
In recent years it has become apparent that the tumour suppressor functions of p53 are subverted in most (perhaps all) human tumours (reviewed in Levine, 1997) . More than half carry mutations in the p53 gene and data are accumulating to suggest that in perhaps all the remaining tumours the p53 protein is either degraded or functionally compromised post-translationally. It was originally discovered that the activities of p53 were suppressed by at least three viral oncoproteins: it is inactivated in complexes with SV40 T antigen and the adenovirus E1B 55K protein and it is degraded in response to papillomavirus 16 E6 (reviewed by Vousden, 1993) . p53 is also inactivated and degraded when hMdm2 is over-expressed in human osteogenic sarcomas that carry an ampli®cation of the hmdm2 locus (Oliner et al., 1992) . This is because hMdm2 is a negative regulator of p53 through its capacity to bind to the transactivation domain of p53 and suppress transcription and also to target p53 for ubiquitin-dependent, proteasome-mediated proteolysis (Oliner et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997) .
Another key molecule acting in the circuit with hMdm2 to regulate p53 stability is p14 ARF , the product of an alternative open reading frame of the INK4A-ARF locus (Quelle et al., 1995) . This protein stabilizes p53 and induces p53-mediated transcription by binding to and antagonizing the functions of hMdm2 (reviewed in Sherr, 1998) . Products of various oncogenes, such as ras, c-myc and adenovirus E1A, can induce the expression of p14 ARF and hence lead to the stabilization and functional activation of p53 (Zhang et al., 1998; Zindy et al., 1998) . Consequently it is thought that p14 ARF is a tumour suppressor acting at an`oncogene checkpoint' upstream of p53 which speci®cally responds to unscheduled proliferation signals (Sherr, 1998) . Unsurprisingly, in many tumour cells expressing Oncogene (2000) 19, 3439 ± 3444 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: MJ Allday 4 wild type p53, p14 ARF (or the mouse equivalent p19 ARF ) is mutated or deleted whereas it is rarely mutant when p53 is itself mutated (Stott et al., 1998; Eischen et al., 1999; Schmitt et al., 1999; Zhang and Xiong, 1999) . Since wild type p53 appears to negatively regulate p14 ARF gene expression, p14 ARF protein is generally undetectable in normal cells and tissues but is readily detected in the tumour cells with mutant or deleted p53 (Stott et al., 1998; Eischen et al., 1999; our unpublished data) .
Recently it was discovered that p53 is a member of a gene family which includes at least two other members. These p53 homologues are called p73 (Kaghad et al., 1997) and p63 (Yang et al., 1998) which is also known as KET, p40, p51, and p73L (reviewed in Kaelin, 1999) . All three proteins ± p53, p63 and p73 ± have similar structural regions which include an acidic Nterminal transactivation domain, a central DNA binding region and a C-terminal oligomerization domain. The DNA binding domains of p63 and p73 mediate an interaction with the canonical binding sites found in p53 target genes, consequently both these p53-related proteins can transactivate p53-responsive promoters. All three genes share a very similar exon/ intron organization, however ± unlike p53 ± both p63 and p73 undergo complex alternative splicing and additionally p63 utilizes a second, internal promoter (Yang et al., 1998) . The variations in splicing (and promoter usage) generate at least six isoforms of both p63 and p73 (reviewed in Kaelin, 1999) .
In the context of this present study of an epithelial cancer which expresses wild type p53, p63 is particularly interesting. Firstly, when the internal promoter for p63 is utilized, proteins are generated which lack the acidic, N-terminal transactivation domain (Yang et al., 1998) . Since these DN-isoforms retain a functional DNA binding domain they can compete for promoter occupation and inhibit p53-(and p63-) mediated transactivation. Such a dominantnegative phenotype is operationally similar to that displayed by some`gain of function' p53 mutants. Also like many p53 mutants the DN-isoforms lack the ability to induce apoptosis that is exhibited by the full-length p63 protein. Critically, several studies showed that p63 is extremely important in the growth and development of epithelial tissues. Expression has been demonstrated in a variety of mouse and human tissues including the proliferating basal and suprabasal cells of epithelium in epidermis, cervix, urothelium and prostate. Only the dominant-negative DN forms of p63 were generally detected in these dividing cells so a role in the regulation of p53 function has been hypothesized (Yang et al., 1998 . Studies on mice homozygous for a disrupted p63 gene (p63-knockout mice) established a strong correlation between the expression of p63 in the progenitor cells in basal epithelia with an absolute requirement for p63 in the normal development of strati®ed squamous forms of epithelium Mills et al., 1999 ). Most recently, high level expression of the DN-p63 was demonstrated in anaplastic human keratinocytes (Parsa et al., 1999) .
In the study presented here, molecular and immunohistochemical analyses were performed on 25 primary undierentiated NPC tumours from the Department of Pathology, University of Hong Kong. Samples were obtained as endoscopic biopsies with tissues snap frozen in liquid nitrogen as well as processed for routine histopathology. In ®ve cases samples were also obtained from normal nasopharyngeal tissue adjacent to the invasive tumour.
A comprehensive molecular analysis of the p53 gene in each tumour was performed and the results (summarized in Table 1 ) were consistent with most previous reports (Eert et al., 1992; Lo et al., 1992; Spruck et al., 1992; Sun et al., 1992) in that no mutations or micro-deletions were found. Immunohistochemistry for p53 expression showed that many of the malignant epithelial cells in the tumours expressed readily detectable levels of nuclear p53 (summarized in Table 2 ). Again this was consistent with previous reports (Niedobitek et al., 1993; Sheu et al., 1995; Murono et al., 1999) .
Over-expression of hMdm2, resulting from gene ampli®cation (Oliner et al., 1992) or post-translational mechanisms (Capoulade et al., 1998) has been reported in a variety of tumours that express wild type p53. Therefore a subset of the NPC series (for which good quality paran-sections were available) were stained for hMdm2 using the SMP14 monoclonal antibody. Nine out of 12 tumours and the normal tissues were negative for hMdm2 but a low level of protein was detected in occasional cells in two tumours and what was judged to be a high level expression in small foci was found in one case (summarized in Table 2 ). The single tumour with over-expression of hMdm2 is clearly not representative, so we concluded that overexpression of hMdm2 is not a general mechanism for the inactivation of p53 in undierentiated NPC. Genetic alterations at the INK4A-ARF locus commonly occur in a wide spectrum of human cancers (reviewed in Foulkes et al., 1997; Ruas and Peters, 1998) . Many involve homozygous deletions, which simultaneously disrupt the genes encoding both p14 ARF and p16
INK4A
. Mutations that alter both p14 ARF and p16 INK4A proteins are common and they include frameshifts, microdeletions/insertions and base substitutions. These primarily occur in the 5' end of exon 2 that is shared by p14 ARF and p16
. Since ectopic expression of the N-terminal domain of p14 ARF encoded by exon 1b can cause cell cycle arrest, it was generally assumed that exon 2 mutations were irrelevant to p14 function (Quelle et al., 1997) . However, recently it was demonstrated that exon 2 of p14 ARF is required for its nucleolar localization and the ecient stabilization of p53 (Zhang and Xiong, 1999) . It is now appreciated that many of the exon 2 point mutations found in human tumours disrupt this function, therefore an analysis of this locus was carried out on the current series of NPC.
Although the p16 INK4A gene has been extensively studied in primary NPC, no mutations in exon 2 have been reported (Lo et al., 1995 (Lo et al., , 1996 Sun et al., 1995; Gulley et al., 1998) . The failure to express p16
INK4A in up to 60% of NPC generally results from homozygous deletion or quite commonly, methylation of the p16 INK4A promoter (Lo et al., 1996) . Consistent with these reports, SSCP analysis of both genomic DNA and (where possible) cDNA here revealed no mutations in the shared p14 ARF /p16
INK4A exon 2 in 25/25 tumours (summarized in Table 1 ). Furthermore we performed similar SSCP analysis on p14 ARF exon 1b and in 24/25 samples this was judged to be wild type. One tumour produced an aberrant SSCP pattern for exon 1b. DNA sequence analysis showed this to be due to a single base deletion in a run of G-residues (nucleotides 346 ± 348). Currently we do not know the precise functional signi®cance of this sequence change, however, since it is a deletion and introduces a frame-shift we suggest it is a mutation rather then a previously undescribed polymorphism. RT ± PCR analysis showed that p14 ARF mRNA was expressed in all the tumours and samples of normal tissue (representative examples are shown in Figure 1 , middle panel). Together these analyses of the INK4A/ARF locus are consistent with p14 ARF being wild type and therefore not involved in the activation of p53 in at least 24/25 NPC. p14 ARF protein was undetectable by immunohistochemistry in both normal tissue (®ve samples) and 12/12 tumour samples ( Figure  2a ,b and summarized in Table 2 ). In contrast, the same reagents produced nuclear staining with the characteristic nucleolar distribution of p14 ARF in a series of HPV 16-positive cervical carcinomas. Two examples are shown in Figure 2c ,d. The utility and speci®city of the anti-p14 ARF serum was thus convincingly demonstrated. Failure to detect p14 ARF protein, when mRNA is present has been reported previously (Stott et al., 1998) and is entirely consistent with cells expressing both wild type p53 and p14 ARF . We conclude that Sections were scored for the degree of staining using a semiquantitative method described previously (Alldred et al., 1993) .
b The anti-p53 mAb [(DO7) Novocastra] was used at 1/50 dilution (2 mg/ ml) incubating O/N at 48C. Microwave antigen retrieval was for 15 min.
c The anti-Mdm2 mAb [(SMP14) Dako, M7146] was used at 1/25 dilution (6 mg/ml) incubating for 1 h at room temperature. Microwave antigen retrieval was for 15 min Figure 1 Reverse transcription-polymerase chain reaction (RT ± PCR) analysis of DN-p63 and p14 ARF expression in NPC. Total RNA was isolated from snap-frozen tissue samples by homogenization in phenol-guanidinium (RNAzol B, Biogenesis) and cDNA synthesized from 3 mg of total RNA using the Stratagene ProStar system. DN-p63 isoforms were ampli®ed using the primers and PCR conditions described in Yang et al. (1998) . PCR was for 28 cycles, after which reactions were resolved on 1.2% agarose gels and transferred to nylon. Hybridization was then performed with an oligonucleotide speci®c for DN-p63, which was labelled with 32 P-g-ATP using polynucleotide kinase. Exon 1b of p14 ARF was ampli®ed using the primers and thermocycling conditions described by Gazzeri et al. (1998) . Following 25 cycles of PCR, reaction products were resolved on 2% agarose gels, transferred to nylon and hybridized with an exon 1b cDNA from pcDNA3ARF (Stott et al., 1998) . To control for variations in cDNA input, b-actin was ampli®ed from each sample under similar limiting conditions and hybridized with an actin cDNA probe. Lanes T1 and T2 are individual NPC samples. The remaining lanes are paired normal nasopharyngeal epithelium and NPC (e.g. N3, T3) genetic alterations in p14 ARF are not involved in the development of undierentiated NPC.
The dominant negative DN isoforms of p63 are associated with actively proliferating epithelial cells (Yang et al., 1998 Mills et al., 1999; Parsa et al., 1999) . Since they have the capacity to neutralize the functions of p53 associated with transactivation, we determined whether DN-p63 is expressed in normal nasopharyngeal epithelium and undierentiated NPC. Initially 12 tumours ± and where it was available matched normal tissue ± were stained with the panspeci®c anti-p63 mAb 4A4 (Santa Cruz; Yang et al., 1998) . In all the tumours examined the malignant epithelial cells (but not the in®ltrating lymphocytes) stained strongly positive for p63 (for example Figure  3b ± d and summarized in Table 2 ). In the normal tissue, as has been reported for other epithelial sites, only basal and suprabasal cells were positive for p63 (Figure 3a,b, lower right corner) .
Since the currently available antibodies fail to distinguish between DN-p63 and the full-length transactivating forms (TA-p63) the expression in both normal nasopharyngeal tissue and NPC was analysed by RT ± PCR. Using a semi-quantitative approach, employing speci®c DN primers (Yang et al., 1998) and 28 cycles of ampli®cation, the levels of DN-p63 RNA in normal tissue and NPC were compared (Figure 1,  top panel) . Consistently, DN was found to be more abundant in the tumour specimens. The pattern of immunocytochemical staining suggests that this distribution re¯ects the high number of positive cells in tumour relative to the restricted region of expression in the basal proliferating compartment of the normal tissue. However, we cannot formally exclude the possibility that within the normal tissue specimens processed for RT ± PCR there was occult in situ or invasive malignancy.`Normal' tissue expressing relatively high levels of DN-p63 (for instance Figure 1 , N7) could be contaminated in this way. Alternatively this sample may merely contain a higher proportion of basal cells.
Analysis with PCR primers speci®c for TA-p63 and 35 cycles of ampli®cation, revealed that in most tumours (14/22) TA-speci®c mRNA was undetectable under our assay conditions; similarly in most of the normal samples no TA-speci®c RNA was detectable. In eight NPC, low levels of TA expression were evident, however in every one the DN-p63 RNA was judged to be vastly in excess (Figure 4 , compare tracks 2, 4 and 6 with tracks 1, 3 and 5 for representative samples). The tumour from case 24, (Figure 4, track 8 ) was the only sample in which a signi®cant level of TA mRNA was detected. Relatively low levels of TA-speci®c mRNA were also evident in three cervical carcinomas analysed in parallel (Figure 4 , tracks 9 ± 16). The results of this analysis of p63 gene expression (summarized in Tables ARF (see Zhang and Xiong, 1999) . (d) A cervical tumour displaying a more generalized and intense p14 ARF nuclear staining. The anti-p14 ARF goat serum [(C20) Santa Cruz, SC-8613) was used at a 1/100 dilution (2 mg/ml) incubating O/N at 48C. Microwave antigen retrieval was for 15 min DN-p63 in NPC T Crook et al 1 and 2) are all consistent with our hypothesis that p53 is wild type in undierentiated NPC because it is functionally inactivated by an excess of the dominant negative DN isoform of p63. This study was performed in order to determine which cellular factor(s) might be responsible for the inactivation of wild type p53 in undierentiated nasopharyngeal carcinoma. HMdm2 was not commonly over-expressed in a series of 12 tumours, so it seems unlikely that this protein is directly involved in the suppression of p53 activity in NPC. Since overexpression of hMdm2 is normally associated with the degradation of p53, these data are consistent with our observation ± and numerous previous reports (see above) ± that relatively large amounts of p53 can be detected in NPC cells. We have shown that ± like p53 ± the gene encoding p14 ARF is rarely aberrant in NPC. This is clearly consistent with previous studies showing p16 INK4A is not generally mutated in the shared exon 2. The discovery that DN-p63 is the dominant isotype in NPC does however suggest a plausible mechanism by which the p53 present in these tumours is prevented from functioning as a transactivator. If the two proteins compete for binding sites on DNA, DN-p63 The predominant species of p63mRNA in NPC are of the DN form. cDNA prepared as described in the legend to Figure  1 was subjected to independent PCR for the TA and DN isoforms using speci®c primers (Yang et al., 1998) . Thirty-®ve cycles of ampli®cation were performed, after which reactions were resolved on agarose gels and hybridized with TA and DN-speci®c oligonucleotide probes, end-labelled with 32 P-ATP. The TA and DN forms are indicated, as is a non-speci®c (NS) band seen in some samples. Tracks 1 ± 8 show four NPC and tracks 9 ± 16 show four cervical carcinomas will very eectively act as a dominant-negative repressor of p53 function. Previously there has been speculation that an EBV function may be responsible for inactivating p53 in NPC (Niedobiteck et al., 1993; Fries et al., 1996) . We acknowledge that the data here do not exclude this possibility and suggest p63 regulation could easily be a target for the virus. Perhaps an EBV function speci®cally maintains a high level of the DN isoform? An alternative possibility is that NPC derives from basal epithelial cells that are developmentally programmed to express high levels of DN-p63. In either case we suggest that p63 may prove to be a valuable diagnostic marker for these undierentiated, non-keratinizing tumours.
To summarize, the extreme rarity of p53 mutations in primary NPC implies that there is little or no selection for genetic inactivation of p53 in the development of this cancer. Since currently available data suggest that aberrations in the structure or regulation of other cellular proteins can produce the same phenotype as inactivating mutations of p53, we have asked what mechanism might be operating in NPC. Excess hMdm2, mutation/deletion of p14 ARF or excess DN-p63 were all considered suspects. Focusing on these cellular factors has produced data consistent with the hypothesis that undierentiated NPC derive from epithelial progenitor cells in which the high level of DN-p63 suppresses wild type p53 function and thus removes the selection pressure for`loss of function' p53 mutations evolving during tumorigenesis.
